Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals.

Abstract:

BACKGROUND:Amyloid pathology, which is one of the characteristics of Alzheimer's disease (AD), results from altered metabolism of the beta-amyloid (Aβ) peptide in terms of synthesis, clearance, or aggregation. A decrease in cerebrospinal fluid (CSF) level Aβ1-42 is evident in AD, and the CSF ratio Aβ42/Aβ40 has recently been identified as one of the most reliable diagnostic biomarkers of amyloid pathology. Variations in inter-individual levels of Aβ1-40 in the CSF have been observed in the past, but their origins remain unclear. In addition, the variation of Aβ40 in the context of AD studied in several studies has yielded conflicting results. METHODS:Here, we analyzed the levels of Aβ1-40 using multicenter data obtained on 2466 samples from six different cohorts in which CSF was collected under standardized protocols, centrifugation, and storage conditions. Tau and p-tau (181) concentrations were measured using commercially available in vitro diagnostic immunoassays. Concentrations of CSF Aβ1-42 and Aβ1-40 were measured by ELISA, xMAP technology, chemiluminescence immunoassay (CLIA), and mass spectrometry. Statistical analyses were calculated for parametric and non-parametric comparisons, linear regression, correlation, and odds ratios. The statistical tests were adjusted for the effects of covariates (age, in particular). RESULTS:Regardless of the analysis method used and the cohorts, a slight but significant age-independent increase in the levels of Aβ40 in CSF was observed in AD. We also found a strong positive correlation between the levels of Aβ1-40 and p-tau (181) in CSF, particularly in control patients. CONCLUSIONS:These results indicate that an increase in the baseline level of amyloid peptides, which are associated with an increase in p-tau (181), may be a biological characteristic and possibly a risk factor for AD. Further studies will be needed to establish a causal link between increased baseline levels of Aβ40 and the development of the disease.

journal_name

Alzheimers Res Ther

authors

Lehmann S,Dumurgier J,Ayrignac X,Marelli C,Alcolea D,Ormaechea JF,Thouvenot E,Delaby C,Hirtz C,Vialaret J,Ginestet N,Bouaziz-Amar E,Laplanche JL,Labauge P,Paquet C,Lleo A,Gabelle A,Alzheimer’s Disease Neuroimaging Initi

doi

10.1186/s13195-020-00696-1

subject

Has Abstract

pub_date

2020-10-02 00:00:00

pages

123

issue

1

issn

1758-9193

pii

10.1186/s13195-020-00696-1

journal_volume

12

pub_type

杂志文章
  • Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials.

    abstract::Lewy body dementia (LBD), including dementia with Lewy bodies and Parkinson's disease dementia, affects over a million people in the USA and has a substantial impact on patients, caregivers, and society. Symptomatic treatments for LBD, which can include cognitive, neuropsychiatric, autonomic, sleep, and motor features...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-020-00703-5

    authors: Goldman JG,Forsberg LK,Boeve BF,Armstrong MJ,Irwin DJ,Ferman TJ,Galasko D,Galvin JE,Kaufer D,Leverenz J,Lippa CF,Marder K,Abler V,Biglan K,Irizarry M,Keller B,Munsie L,Nakagawa M,Taylor A,Graham T

    更新日期:2020-10-29 00:00:00

  • Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease.

    abstract:INTRODUCTION:There are no empiric data to support guidelines for duration of therapy with antidementia drugs. This study examined whether persistent use of antidementia drugs slows clinical progression of Alzheimer disease (AD) assessed by repeated measures on serial tests of cognition and function. METHODS:Six hundre...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt7

    authors: Rountree SD,Chan W,Pavlik VN,Darby EJ,Siddiqui S,Doody RS

    更新日期:2009-10-21 00:00:00

  • Functional connectivity in cognitive control networks mitigates the impact of white matter lesions in the elderly.

    abstract:BACKGROUND:Cerebrovascular pathology, quantified by white matter lesions (WML), is known to affect cognition in aging, and is associated with an increased risk of dementia. The present study aimed to investigate whether higher functional connectivity in cognitive control networks mitigates the detrimental effect of WML...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0434-3

    authors: Benson G,Hildebrandt A,Lange C,Schwarz C,Köbe T,Sommer W,Flöel A,Wirth M

    更新日期:2018-10-27 00:00:00

  • PERK: a novel therapeutic target for neurodegenerative diseases?

    abstract::Identification of therapeutic targets based on novel mechanistic studies is urgently needed for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and prion disease. Multiple lines of evidence have emerged to suggest that inhibition of the stress-induced endoplasmic reticulum kinase PERK (pro...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt260

    authors: Ma T,Klann E

    更新日期:2014-05-29 00:00:00

  • A language-based sum score for the course and therapeutic intervention in primary progressive aphasia.

    abstract:BACKGROUND:With upcoming therapeutic interventions for patients with primary progressive aphasia (PPA), instruments for the follow-up of patients are needed to describe disease progression and to evaluate potential therapeutic effects. So far, volumetric brain changes have been proposed as clinical endpoints in the lit...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0345-3

    authors: Semler E,Anderl-Straub S,Uttner I,Diehl-Schmid J,Danek A,Einsiedler B,Fassbender K,Fliessbach K,Huppertz HJ,Jahn H,Kornhuber J,Landwehrmeyer B,Lauer M,Muche R,Prudlo J,Schneider A,Schroeter ML,Ludolph AC,Otto M,FTLD

    更新日期:2018-04-25 00:00:00

  • Alzheimer's disease drug-development pipeline: few candidates, frequent failures.

    abstract:INTRODUCTION:Alzheimer's disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N-methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. METHODS:We examined Clinical...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt269

    authors: Cummings JL,Morstorf T,Zhong K

    更新日期:2014-07-03 00:00:00

  • Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody.

    abstract:BACKGROUND:Several monoclonal antibodies for the treatment of Alzheimer's disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid β (Aβ) protofibrils. METHODS:Here we describe the first clinical study with BAN2401. Safety and tolerability were...

    journal_title:Alzheimer's research & therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1186/s13195-016-0181-2

    authors: Logovinsky V,Satlin A,Lai R,Swanson C,Kaplow J,Osswald G,Basun H,Lannfelt L

    更新日期:2016-04-06 00:00:00

  • The relationship of weight change trajectory with medial temporal lobe atrophy in patients with mild Alzheimer's disease: results from a cohort study.

    abstract:INTRODUCTION:Weight loss has been described in 20% to 45% of patients with Alzheimer's disease (AD) and has been associated with adverse outcomes. Various mechanisms for weight loss in AD patients have been proposed, though none has been proven. This study aimed to elucidate a mechanism of weight loss in AD patients by...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0098-1

    authors: Droogsma E,van Asselt D,Bieze H,Veeger N,De Deyn PP

    更新日期:2015-04-06 00:00:00

  • Analysis of brain region-specific co-expression networks reveals clustering of established and novel genes associated with Alzheimer disease.

    abstract:BACKGROUND:Identifying and understanding the functional role of genetic risk factors for Alzheimer disease (AD) has been complicated by the variability of genetic influences across brain regions and confounding with age-related neurodegeneration. METHODS:A gene co-expression network was constructed using data obtained...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00674-7

    authors: Lancour D,Dupuis J,Mayeux R,Haines JL,Pericak-Vance MA,Schellenberg GC,Crovella M,Farrer LA,Kasif S

    更新日期:2020-09-02 00:00:00

  • Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?

    abstract:BACKGROUND:Alzheimer's disease (AD) pathophysiology is mostly (>95%) not inherited in a Mendelian fashion. Such sporadic AD (sAD) forms do not exhibit familial aggregation and are characterized by complex genetic inheritance. Growing evidence indicates that multiple genes contribute to sAD-characteristic endophenotypes...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt165

    authors: Hampel H,Lista S

    更新日期:2013-03-18 00:00:00

  • Early brain connectivity alterations and cognitive impairment in a rat model of Alzheimer's disease.

    abstract:BACKGROUND:Animal models of Alzheimer's disease (AD) are essential to understanding the disease progression and to development of early biomarkers. Because AD has been described as a disconnection syndrome, magnetic resonance imaging (MRI)-based connectomics provides a highly translational approach to characterizing th...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0346-2

    authors: Muñoz-Moreno E,Tudela R,López-Gil X,Soria G

    更新日期:2018-02-07 00:00:00

  • The Third French Alzheimer Plan: analysis of the influence of a national public health initiative on scientific research productivity and impact.

    abstract:INTRODUCTION:The Third National Alzheimer Plan (2008-2012) was a major public health initiative in France that included €200 million of funding for research in Alzheimer disease and related disorders (AD). The aim of this study was to document trends in French academic output in AD following the implementation of the p...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0144-z

    authors: Haeffner-Cavaillon N,Devos P,Ledoux S,Ménard J

    更新日期:2015-09-26 00:00:00

  • Increased Aβ42-α7-like nicotinic acetylcholine receptor complex level in lymphocytes is associated with apolipoprotein E4-driven Alzheimer's disease pathogenesis.

    abstract:BACKGROUND:The apolipoprotein E ε4 (APOE4) genotype is a prominent late-onset Alzheimer's disease (AD) risk factor. ApoE4 disrupts memory function in rodents and may contribute to both plaque and tangle formation. METHODS:Coimmunoprecipitation and Western blot detection were used to determine: 1) the effects of select...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-017-0280-8

    authors: Wang HY,Trocmé-Thibierge C,Stucky A,Shah SM,Kvasic J,Khan A,Morain P,Guignot I,Bouguen E,Deschet K,Pueyo M,Mocaer E,Ousset PJ,Vellas B,Kiyasova V

    更新日期:2017-07-27 00:00:00

  • Systematic reviews on behavioural and psychological symptoms in the older or demented population.

    abstract:INTRODUCTION:Behavioural and psychological symptoms of dementia (BPS) include depressive symptoms, anxiety, apathy, sleep problems, irritability, psychosis, wandering, elation and agitation, and are common in the non-demented and demented population. METHODS:We have undertaken a systematic review of reviews to give a ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt131

    authors: van der Linde RM,Stephan BC,Savva GM,Dening T,Brayne C

    更新日期:2012-07-11 00:00:00

  • Correction to: Neurexin 3 transmembrane and soluble isoform expression and splicing haplotype are associated with neuron inflammasome and Alzheimer's disease.

    abstract::Following publication of the original article [1], the authors reported that Fig. 6 contains a mistake. The Fig. 6F is a duplicate of Fig. 6E of Braak 5. ...

    journal_title:Alzheimer's research & therapy

    pub_type: 已发布勘误

    doi:10.1186/s13195-019-0493-0

    authors: Hishimoto A,Pletnikova O,Lang DL,Troncoso JC,Egan JM,Liu QR

    更新日期:2019-05-07 00:00:00

  • ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study.

    abstract:BACKGROUND:Blood-based biomarkers for Alzheimer's disease (AD) are highly needed in clinic practice. So far, the gold standards for AD diagnosis are brain neuroimaging and beta-amyloid peptide, total tau, and phosphorylated tau in cerebrospinal fluid (CSF); however, they are not attractive for large-scale screening. Bl...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00750-y

    authors: Oliveira Monteiro MPA,Salheb Oliveira DSM,Manzine PR,Crispim Nascimento CM,Dos Santos Orlandi AA,de Oliveira Gomes GA,Dos Santos Orlandi F,Zazzetta MS,Pott-Junior H,Cominetti MR

    更新日期:2021-01-08 00:00:00

  • Kidney function and dementia risk in community-dwelling older adults: the Shanghai Aging Study.

    abstract:BACKGROUND:Association between kidney dysfunction and dementia has been studied in western cohorts, but with inconsistent conclusions which may be due to the different measurements of kidney function. We aim to verify the hypothesis that lower levels of kidney function would be associated with increased risk of inciden...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00729-9

    authors: Wang M,Ding D,Zhao Q,Wu W,Xiao Z,Liang X,Luo J,Chen J

    更新日期:2021-01-11 00:00:00

  • Testing whether the progression of Alzheimer's disease changes with the year of publication, additional design, and geographical area: a modeling analysis of literature aggregate data.

    abstract:BACKGROUND:Our objectives were to develop a disease progression model for cognitive decline in Alzheimer's disease (AD) and to determine whether disease progression of AD is related to the year of publication, add-on trial design, and geographical regions. METHODS:Placebo-controlled randomized AD clinical trials were ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00630-5

    authors: Zhang N,Zheng X,Liu H,Zheng Q,Li L

    更新日期:2020-05-26 00:00:00

  • Should interventions to treat or prevent Alzheimer's disease be tested in a population or as targeted treatment of highly selected study participants?

    abstract::Symptomatic treatments for Alzheimer's disease should retain a place in the advanced stages of disease since their actions on these symptoms, even if not modifying the course of disease, are critical for improving patients' comfort and reducing the burden felt by caregivers, especially those facing behavioral disorder...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt228

    authors: Ousset PJ,Delrieu J,Vellas B

    更新日期:2013-12-11 00:00:00

  • Clinical subtypes of chronic traumatic encephalopathy: literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome.

    abstract::The long-term consequences of repetitive head impacts have been described since the early 20th century. Terms such as punch drunk and dementia pugilistica were first used to describe the clinical syndromes experienced by boxers. A more generic designation, chronic traumatic encephalopathy (CTE), has been employed sinc...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-014-0068-z

    authors: Montenigro PH,Baugh CM,Daneshvar DH,Mez J,Budson AE,Au R,Katz DI,Cantu RC,Stern RA

    更新日期:2014-09-24 00:00:00

  • The association of APOE ε4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study.

    abstract:BACKGROUND:Approximately 25% of the general population carries at least one ε4 allele of the Apolipoprotein E (APOE ε4), the strongest genetic risk factor for late onset Alzheimer's disease. Beyond its association with late-onset dementia, the association between APOE ε4 and change in cognition over the adult life cour...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00740-0

    authors: Gharbi-Meliani A,Dugravot A,Sabia S,Regy M,Fayosse A,Schnitzler A,Kivimäki M,Singh-Manoux A,Dumurgier J

    更新日期:2021-01-04 00:00:00

  • Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.

    abstract:BACKGROUND:Whether age at onset influences Alzheimer's disease (AD) progression and the effectiveness of cholinesterase inhibitor (ChEI) therapy is not clear. We aimed to compare longitudinal cognitive and global outcomes in ChEI-treated patients with early-onset Alzheimer's disease (EOAD) versus late-onset Alzheimer's...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,多中心研究

    doi:10.1186/s13195-017-0294-2

    authors: Wattmo C,Wallin ÅK

    更新日期:2017-08-31 00:00:00

  • Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.

    abstract:BACKGROUND:Disclosure of amyloid positron emission tomography (PET) results to individuals without dementia has become standard practice in secondary prevention trials and also increasingly occurs in clinical practice. However, this is controversial given the current lack of understanding of the predictive value of a P...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0398-3

    authors: de Wilde A,van Buchem MM,Otten RHJ,Bouwman F,Stephens A,Barkhof F,Scheltens P,van der Flier WM

    更新日期:2018-07-28 00:00:00

  • Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.

    abstract::In May 2012, the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia brought together in Montreal experts from around Canada to update Canadian recommendations for the diagnosis and management of patients with neurodegenerative conditions associated with deterioration of cognition. Multiple...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt199

    authors: Soucy JP,Bartha R,Bocti C,Borrie M,Burhan AM,Laforce R,Rosa-Neto P

    更新日期:2013-07-08 00:00:00

  • Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody.

    abstract:BACKGROUND:Amyloid-β (Aβ) immunotherapy is one of the most promising disease-modifying strategies for Alzheimer's disease (AD). Despite recent progress targeting aggregated forms of Aβ, low antibody brain penetrance remains a challenge. In the present study, we used transferrin receptor (TfR)-mediated transcytosis to f...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0377-8

    authors: Syvänen S,Hultqvist G,Gustavsson T,Gumucio A,Laudon H,Söderberg L,Ingelsson M,Lannfelt L,Sehlin D

    更新日期:2018-05-24 00:00:00

  • Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays.

    abstract:BACKGROUND:Amyloid-β 1-42 (Aβ1-42) peptide is a well-established cerebrospinal fluid (CSF) biomarker for Alzheimer's disease (AD). Reduced levels of Aβ1-42 are indicative of AD, but significant variation in the absolute concentrations of this analyte has been described for both healthy and diseased populations. Preanal...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0445-0

    authors: Schauer SP,Mylott WR Jr,Yuan M,Jenkins RG,Rodney Mathews W,Honigberg LA,Wildsmith KR

    更新日期:2018-11-28 00:00:00

  • APOE2 orchestrated differences in transcriptomic and lipidomic profiles of postmortem AD brain.

    abstract:BACKGROUND:The application of advanced sequencing technologies and improved mass-spectrometry platforms revealed significant changes in gene expression and lipids in Alzheimer's disease (AD) brain. The results so far have prompted further research using "multi-omics" approaches. These approaches become particularly rel...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0558-0

    authors: Lefterov I,Wolfe CM,Fitz NF,Nam KN,Letronne F,Biedrzycki RJ,Kofler J,Han X,Wang J,Schug J,Koldamova R

    更新日期:2019-12-30 00:00:00

  • Study partners: essential collaborators in discovering treatments for Alzheimer's disease.

    abstract:BACKGROUND:Global leaders have set an ambitious goal of developing interventions to effectively treat or prevent Alzheimer's disease by 2025. CASE PRESENTATION:Achieving this goal will require clinical trials to test promising interventions, yet Alzheimer's researchers are confronting a clinical trial recruitment cris...

    journal_title:Alzheimer's research & therapy

    pub_type: 社论

    doi:10.1186/s13195-018-0425-4

    authors: Largent EA,Karlawish J,Grill JD

    更新日期:2018-09-27 00:00:00

  • Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease.

    abstract::Autosomal-dominant Alzheimer's disease has provided significant understanding of the pathophysiology of Alzheimer's disease. The present review summarizes clinical, pathological, imaging, biochemical, and molecular studies of autosomal-dominant Alzheimer's disease, highlighting the similarities and differences between...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt59

    authors: Bateman RJ,Aisen PS,De Strooper B,Fox NC,Lemere CA,Ringman JM,Salloway S,Sperling RA,Windisch M,Xiong C

    更新日期:2011-01-06 00:00:00

  • Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study.

    abstract:INTRODUCTION:Curcumin is a polyphenolic compound derived from the plant Curcuma Long Lin that has been demonstrated to have antioxidant and anti-inflammatory effects as well as effects on reducing beta-amyloid aggregation. It reduces pathology in transgenic models of Alzheimer's disease (AD) and is a promising candidat...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt146

    authors: Ringman JM,Frautschy SA,Teng E,Begum AN,Bardens J,Beigi M,Gylys KH,Badmaev V,Heath DD,Apostolova LG,Porter V,Vanek Z,Marshall GA,Hellemann G,Sugar C,Masterman DL,Montine TJ,Cummings JL,Cole GM

    更新日期:2012-10-29 00:00:00